yf_tkr_ALNY · 2026-08-24
Alnylam Pharmaceuticals (ALNY) has drawn market attention after announcing plans to present new clinical and real-world data on its ATTR and hypertension RNAi programs at the ESC Congress 2026 in Munich. See our latest analysis for Alnylam Pharmaceuticals. Despite the ESC Congress announcement, Alnylam Pharmaceuticals’ share price has been under pressure, with the stock down 41% year to date and the 1 year total shareholder return declining 47%, although the 3 year total shareholder return...
Read the original at yf_tkr_ALNY ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。